United Kingdom monkeypox
therapeutics market is expected to register robust growth in the forecast
period, 2023-2027. As per the Disease Control and Prevention (CDC), Monkeypox
virus belongs to the Orthopoxvirus genus in the family Poxviridae. The
Orthopoxvirus genus includes variola virus (which causes smallpox), vaccinia
virus (used in the smallpox vaccine), and cowpox virus. Monkeypox represents a viral disease, is
spreading across Europe and North America at a high growth rate. The illness
causes fever, intense headaches and swollen lymph nodes and has a fatality
ratio of three to six percent, as per the World Health Organization (WHO). This
disease spreads from one person to another by having a close contact with
respiratory secretions and skin lesions. Transmission via droplet respiratory
particles generally requires prolonged face-to-face contact, which puts health
workers, household members and other close contacts of active cases at greater
risk. These risks can be minimized
Growing Population with
Weak Immunization Augments the Market Growth
The expanding population
across the United Kingdom is driving the risk of catching monkeypox especially
those who have weak immune systems. The increase in number of cases of
monkeypox is escalating the need for therapeutics which supports the market
growth. Along with this, people with weak immune system can get the severe
symptoms which sometimes can lead to death. This, in turn, is anticipated to
accelerate the growth of the monkeypox therapeutics market across United
Kingdom.
Extensive R & D
Activities to Manufacture Emergency Drugs Catalyze the Market Growth
The high-quality
visualization provided by proper diagnosis allows physicians to detect, and diagnose,
is acting as significant growth-inducing factor. The spread of monkeypox at a
high rate is propelling the need for emergency drugs for the effective
treatment at the right time is bolstering the growth of the market.
Additionally, researchers across United Kingdom continuously making efforts to
produce drugs in huge amount for providing it to the maximum patients. With
this, research and development activities require extensive investments on
advance equipment and technologies to support the drug development to combat
with the outbreak of monkeypox across the globe. This, in turn, is anticipated
to fuel the growth of the monkeypox market.
Expanding Healthcare
Infrastructure is Expected to Boost the Market Growth
The enhancing infrastructure
and the easy access to the healthcare facilities are some of the significant
growth-inducing factors for the monkeypox therapeutics market. United Kingdom
offers advanced and upgraded healthcare facilities to their citizens that make
people aware of numerous diseases. Also, the rising awareness among the people
regarding the monkeypox virus is driving the need to be tested if facing any
symptoms. This further inflates the demand for hospitals or clinics for the
effective treatment. All these aforementioned factors estimated to witness the
growth for monkeypox therapeutics market across United Kingdom.
DOWNLOAD FREE SAMPLE REPORT
Market Segmentation
The United Kingdom monkeypox therapeutics
market is segmented into treatment, end
user, regional
distribution, and competitive landscape. Based on treatment, the market is
divided into smallpox vaccine, antivirals, vaccinia immune globulin (VIG). Based
on end user, the market is segmented into hospitals,
specialty clinics, ambulatory surgical centers, others. To analyze the
market based on the region, the United Kingdom monkeypox therapeutics market is
studied in major regions namely London, Southeast, East Anglia, Scotland,
Southwest, East Midlands, Yorkshire & Humberside, Rest of United Kingdom.
Market Players
Chimerix UK Limited, SIGA Technologies,
Inc., Emergent BioSolutions UK Ltd., Bavarian Nordic A/S, Mylan N.V., Olon
S.p.A., Teva UK Limited are the key market players operating in United Kingdom monkeypox
therapeutics market.
|
Attribute
|
Details
|
|
Base Year
|
2021
|
|
Historic Data
|
2017 –
2020
|
|
Estimated Year
|
2022
|
|
Forecast Period
|
2023
– 2027
|
|
Quantitative Units
|
Revenue in USD Million, and CAGR for 2017-2021 and 2022-2027
|
|
Report coverage
|
Revenue
forecast, company share, competitive landscape, growth factors, and trends
|
|
Segments covered
|
·
Treatment
·
End User
·
Region
|
|
Regional scope
|
London, Southeast, East Anglia, Scotland, Southwest, East
Midlands, Yorkshire & Humberside, Rest of United Kingdom
|
|
Key companies profiled
|
Chimerix UK Limited, SIGA Technologies, Inc., Emergent
BioSolutions UK Ltd., Bavarian Nordic A/S, Mylan N.V., Olon S.p.A., Teva UK
Limited
|
|
Customization scope
|
10%
free report customization with purchase. Addition or alteration to regional
& segment scope.
|
|
Pricing and purchase options
|
Avail customized purchase options to meet your exact research
needs. Explore purchase options
|
|
Delivery Format
|
PDF and Excel
through Email (We can also provide the editable version of the report in
PPT/Word format on special request)
|
Report Scope:
In this report, United Kingdom monkeypox
therapeutics market has been segmented into following categories, in addition
to the industry trends which have also been detailed below:
·
United Kingdom Monkeypox
Therapeutics Market, By Treatment:
o Smallpox Vaccine
o Antivirals
o Vaccinia Immune Globulin (VIG)
·
United Kingdom Monkeypox
Therapeutics Market, By End User:
o Hospitals
o Specialty Clinics
o Ambulatory Surgical Centers
o Others
·
United Kingdom Monkeypox
Therapeutics Market, By Region:
o
London
o
Southeast
o
East
Anglia
o
Scotland
o
Southwest
o
East
Midlands
o Yorkshire & Humberside
o Rest of United Kingdom
Competitive Landscape
Company
Profiles: Detailed
analysis of the major companies present in United Kingdom monkeypox therapeutics
market.
Available Customizations:
With the given market data, TechSci Research offers
customizations according to a company’s specific needs. The following
customization options are available for the report:
Company
Information
o Detailed analysis and profiling of
additional market players (up to five).
United Kingdom monkeypox
therapeutics market
is an upcoming report to be released soon. If you wish an early delivery of
this report or want to confirm the date of release, please contact us at [email protected]